Litigation Details for Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2022)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2022-08-02
Court	District Court, N.D. West Virginia	Date Terminated
Cause	28:1338 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	Plaintiff	Referred To	James P. Mazzone
Parties	MYLAN PHARMACEUTICALS INC.
Patents	7,303,747; 7,608,261; 8,092,803
Attorneys	David I. Berl
Firms	Rakoczy Molino Mazzochi Siwik, LLP
Link to Docket	External link to docket

The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2023-04-19	427	Order	11-12). The patent it cites, U.S. Patent No. 8,092,803, does not support this…the “Dosing Patents”) (Dkt. 146, ‘601 patent; Dkt. 146, ‘572 patent); and U.S. Patent No. 11,104,715… have no patentable weight. C. Manufacturing Patent or Tustian Patents (The ‘715 Patent) …are: U.S. Patent No. 11,084,865 (“the ‘865 patent” or the “Formulation Patent”) (Dkt. 146, ‘865…‘865 patent); U.S. Patent Nos. 10,888,601 (“the ‘601 patent”) and 11,253,572 (“the ‘572 patent	External link to document
2024-01-31	692	Memorandum & Opinion	FOLLOWING BENCH TRIAL In U.S. Patent No. 7,303,747 (“the ‘747 patent”), which published February 9… b) ’747 Patent Defendants also have asserted that U.S. Patent No. 7,303,747, assigned… on September 14, 2009. U.S. Patent No. 7,303,747 issued December 4, 2007, and claims priority…for the patent include. . . ,” as used in the ’601 Patent and the ’865 Patent to lack patentable weight…s U.S. Patent No. 11,253,572 (“the ’572 Patent”); Claims 11 and 19 of Regeneron’s U.S. Patent No.	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document